Roivant Sciences Ltd. (ROIV): One of the Best Stocks to Buy According to Joe Edelman [Yahoo! Finance]
Roivant Sciences Ltd. - Common Shares (ROIV)
Company Research
Source: Yahoo! Finance
Roivant Sciences Ltd. (NASDAQ:ROIV) recently won a major legal battle. In March, Roivant's subsidiaries, Genevant and Arbutus, reached a $2.25 billion global settlement with Moderna over a COVID-19 vaccine patent. This settlement drastically improved Roivant's balance sheet, leaving it with over $4.5 billion in cash and zero debt. Institutional investors view this as a war chest that allows the company to fund its entire pipeline through 2028 without needing to dilute shareholders with new stock offerings. These funds are also betting on Brepocitinib to be Roivant's next multibillion-dollar success story following the sale of Telavant to Roche. In late March, the New England Journal of Medicine published positive Phase 3 VALOR trial results for Brepocitinib. The drug achieved a significant 21.6-point improvement in patient scores, which Jefferies analysts called best-in-class. Is Palvella Therapeutics Inc. (PVLA) the Best Performing NASDAQ Stock So Far in 2025? Roivant Sciences L
Show less
Read more
Impact Snapshot
Event Time:
ROIV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ROIV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ROIV alerts
High impacting Roivant Sciences Ltd. - Common Shares news events
Weekly update
A roundup of the hottest topics
ROIV
News
- Roivant Sciences Ltd. (ROIV): David Einhorn Trims Stake [Yahoo! Finance]Yahoo! Finance
- Roivant Sciences: Moderna Settlement And Brepocitinib Support A Long-Term Buy [Seeking Alpha]Seeking Alpha
- Roivant Sciences (ROIV) was given a new $40.00 price target by Piper Sandler.MarketBeat
- Roivant Sciences (ROIV): A Clinical Trial Win Meets a Phase 3 Failure [Yahoo! Finance]Yahoo! Finance
- Ohio governor: Vivek Ramaswamy faces little-known GOP challengers [USA TODAY]USA TODAY
ROIV
Earnings
- 2/6/26 - In-Line
ROIV
Sec Filings
- 4/22/26 - Form 4
- 4/22/26 - Form 4
- 4/22/26 - Form 4
- ROIV's page on the SEC website